There is a large unmet medical need for patients suffering from functional Gastro-intestinal disorders. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic drug in the class...
Location: United States, California, Menlo Park
Investors 1
| Date | Name | Website |
| - | Atheneos V... | atheneosve... |
Mentions in press and media 2
| Date | Title | Description |
| 04.11.2024 | Relief Therapeutics to merge with Renexxion | Pursuant to the terms of the LOI, the transaction will be structured as an equity combination in which Relief would acquire all outstanding shares of Renexxion in exchange for newly issued shares of Relief to be allocated to the Renexxion ... |
| 12.04.2022 | Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment | ROSCREA, Ireland, April 12, 2022 /PRNewswire/ -- Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, announced... |